{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"26.7","value":"23.0"}]}],"title":"Abemaciclib"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"50.4","value":"21.6"}]}],"title":"M2"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"46.4","value":"26.0"}]}],"title":"M20"}],"denoms":[{"counts":[{"groupId":"OG000","value":"322"}],"units":"Participants"}],"description":"PK: Hepatic Clearance of Abemaciclib, and apparent hepatic clearance of its Metabolites M2 and M20","dispersionType":"Geometric Coefficient of Variation","groups":[{"description":"150 mg Abemaciclib orally every 12 hours plus either 1 mg anastrozole or 2.5 mg letrozole orally once daily for 28 days (28 day cycles).","id":"OG000","title":"Abemaciclib + NSAI"}],"paramType":"GEOMETRIC_MEAN","populationDescription":"All randomized participants who received at least one dose of study drug with evaluable PK data.","reportingStatus":"POSTED","timeFrame":"Cycle 1 Day 1; 2 to 4 hours (h) post dose, Cycle 2 Day 1; 3 h post dose; 7 h post dose, Cycle 3 Day 1; pre dose, 3 h post dose","title":"PK: Hepatic Clearance of Abemaciclib, and Apparent Hepatic Clearance of Its Metabolites M2 and M20","type":"SECONDARY","unitOfMeasure":"liters/hour (L/h)"}